NEW YORK — Gene editing firm Synthego on Thursday said it has raised $200 million from a group of new and existing investors.
The funding includes a Series E financing round led by Perceptive Advisors, with new investors SoftBank Vision Fund 2, Declaration Partners, Laurion Capital Management, Logos Capital, GigaFund, and Chimera Investments. Also participating were existing investors Wellington Management, RA Capital Management, and Moore Strategic Ventures.
Redwood City, California-based Synthego said it will use the funds to advance its CRISPR-based research and drug discovery offerings, which include its Halo suite of research tools and Eclipse cell engineering platform. The company said it will also continue development of new technologies, such as its CRISPROff light-based system for precision gene editing, and increase its manufacturing capabilities.
"CRISPR has become a powerful discovery tool, and now the field is at an inflection point with the promise of translating insights into clinical applications to treat a myriad of serious diseases, including cancer and genetic disorders, being within reach," Synthego cofounder and CEO Paul Dabrowski said in a statement. "With Synthego's full stack of proprietary platforms, clinical-grade manufacturing capabilities, strong relationships in industry, academia, and the investor community, we are well positioned to help our customers usher in this new era of genetic and cellular medicines."
The new funding follows a $100 million Series D round Synthego closed in 2020.